Curated News
By: NewsRamp Editorial Staff
December 18, 2025
Cybin Shifts to Nasdaq with 'HELP' Ticker for Mental Health Innovation
TLDR
- Cybin's move to Nasdaq with the 'HELP' ticker could enhance investor visibility and attract growth capital for its mental health treatments.
- Cybin will transfer from NYSE American to Nasdaq on January 5, 2026, changing its ticker to 'HELP' while maintaining its Cboe Canada listing.
- This strategic move supports Cybin's mission to develop innovative mental health treatments, potentially improving care for millions suffering from depression and anxiety.
- Cybin's new 'HELP' ticker symbol on Nasdaq cleverly aligns with its mission to revolutionize mental healthcare through novel psychedelic-based therapies.
Impact - Why it Matters
This news matters because it signals Cybin's strategic positioning for growth in the competitive mental health treatment market. The move to Nasdaq typically provides companies with greater visibility among institutional investors and retail traders, potentially increasing liquidity and valuation. For patients suffering from mental health conditions like major depressive disorder and anxiety, Cybin's progress with novel treatments like CYB003 and CYB004 represents hope for more effective therapies beyond traditional antidepressants. The company's research into psychedelic-derived compounds could revolutionize mental healthcare by addressing treatment-resistant conditions. For investors, this transition may indicate confidence in Cybin's clinical pipeline and future prospects in the rapidly evolving neuropsychiatry sector.
Summary
Cybin Inc., a clinical-stage pharmaceutical company developing next-generation mental health treatments, has announced a significant strategic move to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The transition is scheduled for January 2026, with trading on NYSE American ceasing on January 4th and commencing on Nasdaq under the new ticker symbol "HELP" on January 5th. This move, which also includes maintaining its listing on Cboe Canada under the same "HELP" ticker, represents a pivotal moment for the company as it seeks greater visibility and investor engagement in the competitive biopharmaceutical sector.
At the core of Cybin's mission is revolutionizing mental healthcare through innovative treatments for conditions like major depressive disorder and generalized anxiety disorder. The company's pipeline features promising candidates such as CYB003, a deuterated psilocin analog currently in Phase 3 studies with Breakthrough Therapy Designation from the FDA, and CYB004, a deuterated DMT molecule in Phase 2 studies. These developments position Cybin at the forefront of neuropsychiatry research, addressing the large unmet need for effective mental health treatments that provide durable results for patients suffering from these debilitating conditions.
The announcement was disseminated through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio that provides advanced wire-grade press release syndication and corporate communications solutions. For investors seeking more information, the full press release is available via the provided link, and updates relating to CYBN can be found in the company's newsroom. This strategic exchange transfer comes as Cybin continues to expand its operational footprint across Canada, the United States, the United Kingdom, and Ireland, solidifying its position as a late-stage breakthrough neuropsychiatry company committed to changing the mental health treatment landscape.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cybin Shifts to Nasdaq with 'HELP' Ticker for Mental Health Innovation
